SCHEMBL13635556

SCHEMBL13635556

Cc1cccc(-n2c(=O)ccc3cc(C(=O)NCc4ccccc4)[nH]c32)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
KDM4E B2RXH2 2/20 0.45
MAPT P10636 3/20 0.44
KLK1 P06870 1/20 0.44
ALDH1A1 P00352 2/20 0.44
ROCK2 O75116 1/20 0.43
PIM1 P11309 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
TP53 P04637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
IDO1 P14902 1/20 0.42
TSHR P16473 1/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14886527 0.90 MAPT (0.52) MEN1KMT2ACA12CA1CA2
SCHEMBL10059692 0.89 SRC (0.51) MEN1KMT2ACA12CA1CA2
SCHEMBL10079694 0.84 CA12 (0.52) MEN1KMT2ACA12CA1CA2
SCHEMBL10059668 0.83 LMNA (0.48) LMNAMEN1KMT2ACA12CA1
SCHEMBL10059611 0.83 CA12 (0.48) LMNAMEN1KMT2ACA12CA1
SCHEMBL17612713 0.82 CA12 (0.47) LMNAMEN1KMT2ACA12CA1
SCHEMBL13635543 0.82 ALKBH5 (0.53) LMNAMEN1KMT2AKDM4EMAPT
SCHEMBL10059642 0.81 PDE2A (0.48) MEN1KMT2ACA12CA1CA2
SCHEMBL10059571 0.81 MEN1 (0.51) MEN1KMT2ACA12CA1CA2
SCHEMBL14886292 0.80 MAPT (0.53) LMNAMEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130102597-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2013-04-25 US disclosed
US-8304413-B2 Compounds and methods for treating inflammatory and fibrotic disorders INTERMUNE, INC. (US) 2012-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102597-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS MAP3K8, MAP3K1, MAP3K6 LMNA 2852/4885MEN1 4879/4885KMT2A 4403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.